Abstract: The disclosed tamper-evident closure (100) encloses a medical access device (200), such as a vascular access device and includes an actuatable door (127) to create an optional access point (113) for accommodating various arrangements of medical access devices within the tamper-evident closure. The tamper-evident closure comprises a holding cavity (110), an access point into the holding cavity, an actuatable door covering the access point, and a hinge (127c) connecting the actuatable door to the holding cavity.

Abstract: Silicon carbide (SiC) wafers and related methods are disclosed that include large diameter SiC wafers with wafer shape characteristics suitable for semiconductor manufacturing. Large diameter SiC wafers are disclosed that have reduced deformation related to stress and strain effects associated with forming such SiC wafers. As described herein, wafer shape and flatness characteristics may be improved by reducing crystallographic stress profiles during growth of SiC crystal boules or ingots. Wafer shape and flatness characteristics may also be improved after individual SiC wafers have been separated from corresponding SiC crystal boules. In this regard, SiC wafers and related methods are disclosed that include large diameter SiC wafers with suitable crystal quality and wafer shape characteristics including low values for wafer bow, warp, and thickness variation.

Abstract: Silicon carbide (SiC) materials including SiC wafers and SiC boules and related methods are disclosed that provide large dimension SiC wafers with reduced crystallographic stress. Growth conditions for SiC materials include maintaining a generally convex growth surface of SiC crystals, adjusting differences in front-side to back-side thermal profiles of growing SiC crystals, supplying sufficient source flux to allow commercially viable growth rates for SiC crystals, and reducing the inclusion of contaminants or non-SiC particles in SiC source materials and corresponding SiC crystals. By forming larger dimension SiC crystals that exhibit lower crystallographic stress, overall dislocation densities that are associated with missing or additional planes of atoms may be reduced, thereby improving crystal quality and usable SiC crystal growth heights.

Abstract: The invention provides compositions and methods for treating ovarian cancer. Specifically, the invention relates to administering a genetically modified T cell having ?-folate receptor (FR?) binding domain and CD27 costimulatory domain to treat ovarian cancer. In an embodiment, the FR? binding domain is fully human, thereby preventing a host immune response.

Abstract: The disclosed tamper-evident closure encloses a medical access device, such as a vascular access device, such that it will be visibly apparent if the medical access device contained in the tamper-evident closure becomes exposed. The tamper-evident closure cannot be reapplied over the medical access device in a way to look the same as it did prior to exposing the medical access device. The tamper-evident closures comprise a securing strap with a first securing strap portion secured to the first part of the tamper-evident closure, a second securing strap portion with a free end for securing to a second part of the tamper-evident closure, and an area of weakness separating the first securing strap portion from the second securing strap portion. The force to break the area of weakness is less than the force to separate the securing strap from the first part or second part.

Abstract: The invention provides specific synthetic chimeric xenonucleic acid guide RNA; s(XNA-gRNA) for enhancing crispr mediated genome editing efficiency. The invention also provides methods and compositions for inducing CRISPR/Cas-based gene editing/regulation (e.g., genome editing or gene expression) of a target nucleic acid (e.g., target DNA or target RNA) in a cell. The methods include using single guide RNAs (sgRNAs) that have been chemically modified with xeno nucleic acids which enhance gene regulation of the target nucleic acid in a primary cell for use in ex vivo therapy or in a cell in a subject for use in in vivo therapy. Additionally, provided herein are methods for preventing or treating a genetic disease in a subject by administering a sufficient amount of a sgRNA that has been chemically modified with xeno nucleic acids to correct a mutation in a target gene associated with the genetic disease.

Abstract: A system including a network interface and a processing circuit is provided. The processing circuit includes one or more processors coupled to non-transitory memory. The processing circuit is structured to receive a request for a multiple custody linkage between user devices. The multiple custody linkage includes a digital connection between the user devices that allows shared access to a resource. The resource includes at least one of a physical object or information. The processing circuit is further structured to perform a validation process based on information in the request for the multiple custody linkage to determine if a violation of a security protocol exists. The security protocol is associated with security of the resource. The processing circuit is further structured to, in response to determining no violation of the security protocol exists, activate the multiple custody linkage between the user devices to allow the shared access to the resource.

Abstract: The invention relates to a method for enriching a target polynucleotide sequence containing a genetic variation said method comprising: (a) providing two primers targeted to said target polynucleotide sequence; (b) providing a target specific xenonucleic acid clamp oligomer specific for a wildtype polynucleotide sequence; (c) generating multiple amplicons using PCR under specific temperature cycling conditions; and (d) detecting said amplicons.

Abstract: Silicon carbide (SiC) wafers and related methods are disclosed that include large diameter SiC wafers with wafer shape characteristics suitable for semiconductor manufacturing. Large diameter SiC wafers are disclosed that have reduced deformation related to stress and strain effects associated with forming such SiC wafers. As described herein, wafer shape and flatness characteristics may be improved by reducing crystallographic stress profiles during growth of SiC crystal boules or ingots. Wafer shape and flatness characteristics may also be improved after individual SiC wafers have been separated from corresponding SiC crystal boules. In this regard, SiC wafers and related methods are disclosed that include large diameter SiC wafers with suitable crystal quality and wafer shape characteristics including low values for wafer bow, warp, and thickness variation.

Abstract: Compositions and methods for treatment of cancer according to aspects of the present disclosure comprise compounds comprising or consisting of: structural formula (I) or (II) disclosed herein, or a salt, isomer, or derivative thereof.

Abstract: The present invention includes compositions and methods for treating T cell lymphomas and leukemias. In certain aspects, the compositions and methods include CAR T cells targeting CD2, CD5, or CD7 and modified cells wherein CD2, CD5, or CD7 has been knocked-out.

Abstract: Described herein are methods of eliciting an immune response in human subject in need thereof, the methods including transdermally delivering to the human subject a composition comprising particles, the composition contained in a housing of a microneedle patch device, wherein transdermally delivering includes transdermally delivering an initial dose; transdermally delivering a booster dose within 4-6 weeks of the initial dose; and transdermally delivering a subsequent dose at 1 year or more after delivering the booster dose, wherein no dose is given between the booster dose and the subsequent dose. The composition includes particles including an antigenic multilayer film.

Abstract: Compositions and methods for treatment of cancer according to aspects of the present disclosure comprise compounds comprising or consisting of: structural formula (I) or (II) disclosed herein, or a salt, isomer, or derivative thereof.

Abstract: The invention provides a method for detecting KRAS mutations at one or more of codons, said method comprising the steps of: (a) extracting DNA from a biological sample; (b) assaying the DNA via PCR for KRAS mutations at one or more of codons with at least one set of oligonucleotides, wherein the at least one set of oligonucleotides comprises an allele specific forward primer, a reverse primer, a probe and a xenonucleic acid clamp to block amplification of wild type DNA. The xenonucleic acid clamps have aza-aza, thio-aza and oxy-aza chemical functionality.

Abstract: The invention provides compositions and methods for adoptive T cell therapy in treating a variety of disorders including cancer, infections, and autoimmune disorders. In one embodiment, the invention provides a universal immune receptor (UnivIR) that comprises an extracellular label binding domain, a transmembrane domain, and a cytoplasmic domain or otherwise an intracellular domain.

Abstract: The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of FSHR. The invention provides novel peptides that specifically bind to Follicle-stimulation hormone receptor (FSHR).

Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.

Abstract: A method for reducing excess pressure in isochoric systems that involves providing a rigid and sealable master container, placing a primary subsystem comprised of biological matter into the master container, placing a secondary subsystem into the master container, removing bulk gas phase from the master container, sealing the master container, cooling the master container to a desired sub-0° Centigrade storage temperature, maintaining the master container at the storage temperature for a storage period, warming the master container to a temperature that is greater than the equilibrium melting point of the primary subsystem, unsealing the master container, and removing the biological matter from the master container. The secondary subsystem is a liquid that is immiscible with water and has a positive coefficient of thermal expansion that is greater in absolute magnitude than the coefficient of thermal expansion of water at sub-0° Centigrade temperatures. An apparatus for performing the foregoing method steps.

Abstract: The invention features a prospective respiratory motion compensation technique for cardiovascular magnetic resonance imaging of the whole-heart of a free-breathing subject.

Abstract: A method for providing secure single sign on includes receiving a first data object from an application hosting server, the first data object indicating at least a service provider name and identifying a configuration file corresponding to the service provider name, wherein the configuration file includes at least trusted identity information. The method also includes determining, using the configuration file corresponding to the service provider name, whether the first data object is valid and, in response to a determination that the first data object is valid, generating a response message.